The Wittrup lab at the @kochinstitute @MIT. Protein engineering for cancer immunotherapy. Run by lab members @MITChemE @MITdeptofBE
Cambridge, MA
Joined January 2022
- Tweets72
- Following292
- Followers320
- Likes3K
Wittrup Lab retweeted
How AI Revolutionized Protein Science, but Didn’t End It
3 years ago, Google’s AlphaFold pulled off the biggest artificial intelligence breakthrough in science to date, accelerating molecular research and kindling deep questions about why we do science.
quantamagazine.org/how-ai-re…
Wittrup Lab retweeted
A bit late sharing but excited to see my PhD work out in @NatureComms! Huge shoutout to all of my coauthors and my PhD advisor for helping get this across the finish line. Not much has changed since the preprint so I’ll link to that tweetorial below nature.com/articles/s41467-0…
Wittrup Lab retweeted
Palmeri et al. fused an agonistic anti-4-1BB Ab and the collagen-binding domain of LAIR1 (ɑ4-1BB-LAIR). However, treating mouse tumor models with ɑ4-1BB-LAIR i.t. plus an Ab specific for tumor-expressed antigen [...] bit.ly/4ackehO  @josephrpalmeri  @theWittrupLab
Wittrup Lab retweeted
.@TheWittrupLab reported the development of a tumor-anchored É‘4-1BB agonist, which consists of a É‘4-1BB antibody fused to the collagen-binding protein leukocyte associated immunoglobulin like receptor. @kochinstitute
🔗 go.nature.com/3UZDvhT
Wittrup Lab retweeted
Kicking off 2024 by sharing a preprint of my PhD work! We report an engineered cytokine therapy that elicits some of the most profound anti-tumor immunity we have seen in our labs' preclinical work.
Preprint and walk-through below:
Local delivery of cell surface-targeted immunocytokines programs systemic anti-tumor immunity biorxiv.org/cgi/content/shor… #biorxiv_immuno
Curious what we’ve been up to recently? Check out our posters at #SITC23 today to learn about collagen anchored cytokine therapy in canines (1094) and how Tregs constrain responses to collagen anchored anti-4-1BB agonist antibody therapy (1224)!
Wittrup Lab retweeted
Excited to share that the second paper from my post-doc is out! This was a very fun 4-way collaboration between the @stefanispranger, White, and @TheWittrupLab labs at @MIT and the Garcia lab at @Stanford! @kochinstitute @MITBiology @sitcancerECS insight.jci.org/articles/vie…
Wittrup Lab retweeted
In other news, I’m back in NH today with my @TheWittrupLab friends to run a Ragnar road race. Follow along as we run a 200 mile relay over the next 30 hours 😤😤😤
Wittrup Lab retweeted
SPOTLIGHT: To improve the therapeutic window of IL-2 and IL-12, @MIT evaluated canine-ized collagen-binding IL-2 and IL-12 in pet beagles with spontaneous soft tissue sarcomas 👉 bit.ly/3mDubkX
Wittrup Lab retweeted
"I think that back and forth between the industry and the clinical settings and open communication helps to
find the next boundary that we can push."
Watch the video of our latest with/in/sight, "Anchor Management."
youtu.be/lJmLu7lB8zM
By anchoring powerful anti-cancer immunotherapies to tumors, KI engineers found a way that could minimize their very serious toxic side effects.
But how are they working to transform this lab discovery into a clinical treatment?
Join us Tue, April 4: bit.ly/Apr2023-wis
Wittrup Lab retweeted
Successfully defended my PhD in chemical engineering from @MIT last week. Wouldn’t have made it through this journey without the endless support of my colleagues in @TheWittrupLab and all of my friends and family. Excited for the next adventure!
Wittrup Lab retweeted
Join Koch Institute immune engineers and @ankyratx CEO Howard Kaufman on April 4 to hear how they are taking anchored immunotherapy against solid tumors from the lab bench to the cancer clinic.
Register: bit.ly/Apr2023-wis
ALT Join us for Solutions with/in/sight: Anchor Management on Tuesday, April 4 for a program featuring a new immune engineering approach for treating solid tumors. Learn about the bench-to-bedside evolution of two Koch Institute research projects whose convergence spun out a company and a ongoing collaboration to bring anchored immunotherapy to patients. Featured presenters: Howard Kaufman, Stefani Spranger, Darrel Irvine, and Dane Wittrup. Register to attend in person or on Zoom at the link in the post.
Wittrup Lab retweeted
SPOTLIGHT: To enhance the effectiveness and safety of stimulatory receptor agonist antibodies, researchers at @MITdeptofBE developed a collagen-targeting 4-1BB agonist Ab and delivered it directly into B16 melanoma tumors along [...] ow.ly/EjR650N622g
Wittrup Lab retweeted
Excited to share my first first author paper and a large part of my PhD work. A quick tweetorial 🧵 (1/13)
biorxiv.org/content/10.1101/…
Check out our latest work on the role Tregs play in limiting responses to local anti-4-1BB therapy. Also if you’re looking to hire post docs to study T cell biology/dysfunction Joseph is graduating soon and looking for positions!!
Excited to share my first first author paper and a large part of my PhD work. A quick tweetorial 🧵 (1/13)
biorxiv.org/content/10.1101/…
Huge congrats to Dr. Anthony Tabet on a phenomenal PhD defense today.
Anthony was co-advised by the @AnikeevaLab and leveraged the unique skill sets of both labs to push the boundaries of cancer neuroimmunology. Excited to see what you accomplish next!
You’re unable to view this Post because this account owner limits who can view their Posts. Learn more
Wittrup Lab retweeted
Up at BATS today, we have...
@lauren_duhamel (@TheWittrupLab)
Engineering Strategies to Modulate CD45 Signaling for Cancer Immunotherapy
Kwan Yoon (@Geneticdesigner)
Engineering Bidirectional Plant-microbe Signaling to Combat Plant Disease
be.mit.edu/news-events/bats/…
